IRIS
MORSIA, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.759
AS - Asia 1.244
EU - Europa 909
SA - Sud America 365
AF - Africa 104
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.384
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.699
SG - Singapore 346
VN - Vietnam 334
IT - Italia 278
BR - Brasile 274
CN - Cina 238
RU - Federazione Russa 213
HK - Hong Kong 130
FR - Francia 84
DE - Germania 70
IE - Irlanda 51
IN - India 47
CI - Costa d'Avorio 46
GB - Regno Unito 43
AR - Argentina 38
FI - Finlandia 38
NL - Olanda 33
MX - Messico 31
BD - Bangladesh 21
SE - Svezia 21
AT - Austria 20
CA - Canada 18
ID - Indonesia 17
MA - Marocco 17
PL - Polonia 16
JP - Giappone 15
ES - Italia 14
VE - Venezuela 13
EC - Ecuador 12
IQ - Iraq 12
ZA - Sudafrica 12
TR - Turchia 11
CO - Colombia 9
PE - Perù 8
TH - Thailandia 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 6
PH - Filippine 6
PK - Pakistan 6
PY - Paraguay 6
KR - Corea 5
SN - Senegal 5
TN - Tunisia 5
AZ - Azerbaigian 4
CL - Cile 4
CZ - Repubblica Ceca 4
EG - Egitto 4
JO - Giordania 4
KZ - Kazakistan 4
LT - Lituania 4
MY - Malesia 4
NP - Nepal 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
SA - Arabia Saudita 3
AL - Albania 2
BW - Botswana 2
CR - Costa Rica 2
ET - Etiopia 2
GR - Grecia 2
JM - Giamaica 2
KE - Kenya 2
MT - Malta 2
PT - Portogallo 2
RS - Serbia 2
TW - Taiwan 2
TZ - Tanzania 2
UA - Ucraina 2
AU - Australia 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
TG - Togo 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 4.384
Salva come PNG Salva come JPEG
Città #
Ashburn 451
Singapore 209
Dallas 196
San Jose 141
Hong Kong 124
Ho Chi Minh City 116
Boardman 91
Los Angeles 86
Hanoi 79
Beijing 53
Dublin 51
Hefei 49
Abidjan 46
Lauterbourg 45
New York 45
Ancona 41
Council Bluffs 41
Munich 40
Chandler 38
Chicago 36
Moscow 34
Buffalo 33
The Dalles 29
Helsinki 25
São Paulo 24
Denver 23
Orem 22
Milan 21
Turin 19
Brooklyn 17
Rome 17
Washington 17
Salt Lake City 16
Chennai 15
Frankfurt am Main 15
Haiphong 15
Santa Clara 15
Amsterdam 13
Turku 13
Mexico City 12
Da Nang 11
London 11
Warsaw 11
Guangzhou 10
Tokyo 10
San Francisco 9
Stockholm 9
Bari 8
Houston 8
Montreal 8
Nuremberg 8
Seattle 8
Tashkent 8
Boston 7
Manchester 7
Naples 7
Rio de Janeiro 7
Shanghai 7
Atlanta 6
Caracas 6
Elk Grove Village 6
Hải Dương 6
Johannesburg 6
Mumbai 6
Ninh Bình 6
Tampa 6
Vienna 6
Baghdad 5
Bangkok 5
Can Tho 5
Dakar 5
Falconara Marittima 5
Lima 5
Medellín 5
Miami 5
New Delhi 5
North Charleston 5
Osimo 5
Paris 5
Wuhan 5
Baku 4
Biên Hòa 4
Bologna 4
Brasília 4
Campinas 4
Cardiff 4
City of London 4
Clifton 4
Columbus 4
Fortaleza 4
Guarulhos 4
Guayaquil 4
Huế 4
Lawrence 4
Perugia 4
Phoenix 4
Poplar 4
Prague 4
Princeton 4
Querétaro 4
Totale 2.726
Salva come PNG Salva come JPEG
Nome #
Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region 162
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report 154
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 148
A rare case of aCML associated with CNS involvement and with aggressive clinical course 136
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 133
Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis 120
Anticoagulation and vessel recanalization in cirrhotic patients with splanchnic vein thrombosis: A multidisciplinary “real life” experience 120
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications 119
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 118
Bone Marrow Adipose Tissue 114
Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints 112
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 111
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 104
Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience 104
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 99
AL amyloidosis: an overview on diagnosis, staging system, and treatment 99
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 98
Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases 98
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients 96
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 95
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 93
Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous Lymphomas 92
Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes 92
Is There a Correlation Between Immune Thrombocytopenia and Immunoglobulin G4-Related Disease? 92
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 91
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights 90
Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project 89
Myeloproliferative Neoplasms with Monocytosis 80
Expression of Paraoxonase-2 in Different Stages of Cutaneous T Cell Lymphoma: Is It a Potential Biomarker for Aggressiveness? 80
P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS? 79
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 79
Epidemiology and Risk Factors for Infections in Myelodysplastic Syndromes 75
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences 70
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI) 70
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 68
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 64
Long-Term Efficacy of Psoralen Plus Ultraviolet a Irradiation and Low-Dose Interferon-Alpha Therapy According to Conventional and Emerging Clinical Endopoints of Early Stage Cutaneous T Cell Lymphoma 63
Myelofibrosis: challenges for preclinical models and emerging therapeutic targets 63
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients 60
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 59
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis 59
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome 59
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea 57
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic 56
Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients 56
Mutations and thrombosis in essential thrombocythemia 54
IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience 53
Paraoxonase-2 in cutaneous T cell lymphomas. 52
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort 50
Pediatric primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: A retrospective analysis and review of the literature 49
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study 46
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series 44
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice? 11
Totale 4.535
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.073
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.073
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202230 7 1 0 0 0 1 3 2 0 3 6 7
2022/2023157 6 9 7 12 7 9 1 9 26 0 60 11
2023/2024378 37 12 38 44 57 54 11 13 3 28 15 66
2024/20251.011 66 66 38 19 31 53 96 24 171 55 193 199
2025/20262.959 213 252 295 384 311 253 525 260 246 220 0 0
Totale 4.535